Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1974-1982

  Shi, Qizhen ^a,b,c   Wilcox, David A ^a,b,c   Fahs, Scot A ^a   Weiler, Hartmut ^a,b   Wells, Clive W ^b   Cooley, Brian C ^b   Desai, Drashti ^a,b,c   Morateck, Patricia A ^a   Gorski, Jack ^a,b   Montgomery, Robert R ^a,b,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B DOMAIN DELETED BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; GLYCOPROTEIN IB ALPHA; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL BASED GENE THERAPY; CELL TRANSFER; CONTROLLED STUDY; HEMOPHILIA A; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SPLEEN CELL; TARGET CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; BLOOD PLATELETS; FACTOR VIII; GENE THERAPY; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; PHENOTYPE; PLATELET ACTIVATION; TRANSGENES; VON WILLEBRAND FACTOR;

EID: 33745864802     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28416     Document Type: Article

References (56)

1. Kaufman, R.J. 1999. Advances toward gene therapy for hemophilia at the millennium. Hum. Gene Ther. 10:2091-2107.
2. Furie, B., Limentani, S.A., and Rosenfield, C.G. 1994. A practical guide to the evaluation and treatment of hemophilia. Blood. 84:3-9.
3. Scandella, D.H. 2000. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin. Thromb. Hemost. 26:137-142.
4. Rosenberg, J.B., et al. 1998. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J. Clin. Invest 101:613-624.
5. Do, H., Healey, J.F., Waller, E.K., and Lollar, P. 1999. Expression of factor VIII by murine liver sinusoidal endothelial cells. J. Biol. Chem. 274:19587-19592.
6. High, K.A. 2003. Gene transfer as an approach to treating hemophilia. Semin. Thromb. Hemost. 29:107-120.
7. Roth, D.A., Tawa, N.E., Jr., O'Brien, J.M., Treco, D.A., and Selden, R.F. 2001. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N. Engl. J. Med. 344:1735-1742.
8. Saenko, E.L., Ananyeva, N.M., Moayeri, M., Ramezani, A., and Hawley, R.G. 2003. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr. Gene Ther. 3:27-41.
9. Yarovoi, H.V., et al. 2003. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 102:4006-4013.
10. Kootstra, N.A., Matsumura, R., and Verma, I.M. 2003. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol. Ther. 7:623-631.
11. Tiede, A., et al. 2003. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther. 10:1917-1925.
12. Moayeri, M., Ramezani, A., Morgan, R.A., Hawley, T.S., and Hawley, R.G. 2004. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol. Ther. 10:892-902.
13. Ye, P., et al. 2004. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol. Ther. 10:117-126.
14. Xu, L., et al. 2005. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc. Natl. Acad. Sci. U. S. A. 102:6080-6085.
15. Scallan, C.D., et al. 2003. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood. 102:3919-3926.
16. Kelley, K., Verma, I., and Pierce, G.F. 2002. Gene therapy: reality or myth for the global bleeding disorders community? Haemophilia. 8:261-267.
17. Powell, J.S., et al. 2003. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood. 102:2038-2045.
18. Chuah, M.K., Collen, D., and VandenDriessche, T. 2004. Clinical gene transfer studies for hemophilia A. Semin. Thromb. Hemost. 30:249-256.
19. Kaufman, R.J., Wasley, L.C., and Dorner, A.J. 1988. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J. Biol. Chem. 263:6352-6362.
20. Denis, C., et al. 1998. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. U. S. A. 95:9524-9529.
21. Rosenberg, J.B., Greengard, J.S., and Montgomery, R.R. 2000. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:2689-2695.
22. Shi, Q., Wilcox, D.A., Fahs, S.A., Kroner, P.A., and Montgomery, R.R. 2003. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol. Genet. Metab. 79:25-33.
23. Wilcox, D.A., et al. 2003. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J. Thromb. Haemost. 1:2477-2489.
24. Nachman, R., Levine, R., and Jaffe, E.A. 1977. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J. Clin. Invest. 60:914-921.
25. Sprandio, J.D., Shapiro, S.S., Thiagarajan, P., and McCord, S. 1988. Cultured human umbilical vein endothelial cells contain a membrane glycoprotein immunologically related to platelet glycoprotein Ib. Blood. 71:234-237.
26. Konkle, B.A., Shapiro, S.S., Asch, A.S., and Nachman, R.L. 1990. Cytokine-enhanced expression of glycoprotein Ib alpha in human endothelium. J. Biol. Chem. 265:19833-19838.
27. Rajagopalan, V., Essex, D.W., Shapiro, S.S., and Konkle, B.A. 1992. Tumor necrosis factor-alpha modulation of glycoprotein Ib alpha expression in human endothelial and erythroleukemia cells. Blood. 80:153-161.
28. Oleksowicz, L., Dutcher, J.P., DeLeon-Fernandez, M., Paietta, E., and Etkind, P. 1997. Human breast carcinoma cells synthesize a protein immunorelated to platelet glycoprotein-Ib alpha with different functional properties. J. Lab. Clin. Med. 129:337-346.
29. Wilcox, D.A., Olsen, J.C., Ishizawa, L., Griffith, M., and White, G.C. 1999. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 96:9654-9659.
30. Rodriguez, M.H., et al. 2002. Expression of coagulation factor IX in a haematopoietic cell line. Thromb. Haemost. 87:366-373.
31. Berridge, M.V., Ralph, S.J., and Tan, A.S. 1985. Cell-lineage antigens of the stem cell-megakaryocyte-platelet lineage are associated with the platelet IIb-IIIa glycoprotein complex. Blood. 66:76-85.
32. Phillips, D.R., Charo, I.F., Parise, L.V., and Fitzgerald, L.A. 1988. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 71:831-843.
33. Uzan, G., Prandini, M.H., and Berthier, R. 1995. Regulation of gene transcription during the differentiation of megakaryocytes. Thromb. Haemost. 74:210-212.
34. Block, K.L., and Poncz, M. 1995. Platelet glycoprotein IIb gene expression as a model of megakaryocyte-specific expression. Stem Cells. 13:135-145.
35. Tronik-Le, R.D., Roullot, V., Schweitzer, A., Berthier, R., and Marguerie, G. 1995. Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by the platelet glycoprotein alpha IIb promoter. J. Exp. Med. 181:2141-2151.
36. Tropel, P., et al. 1997. A 2.7-kb portion of the 5′ flanking region of the murine glycoprotein alphaIIb gene is transcriptionally active in primitive hematopoietic progenitor cells. Blood. 90:2995-3004.
37. Fang, J., et al. 2005. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 106:2671-2679.
38. Shi, Q., et al. 2004. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J. Thromb. Haemost. 2:1989-1997.
39. Verbruggen, B., et al. 1995. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb. Haemost. 73:247-251.
40. Wagner, D.D. 1990. Cell biology of von Willebrand factor. Annu. Rev. Cell Biol. 6:217-246.
41. Pittman, D.D., et al. 1993. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 81:2925-2935.
42. Thomas, K.B., et al. 1999. Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters. Haemophilia. 5:17-25.
43. Yoshioka, A., Fukutake, K., Takamatsu, J., and Shirahata, A. 2003. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int. J. Hematol. 78:467-474.
44. Gringeri, A., et al. 2004. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br. J. Haematol. 126:398-404.
45. Haberichter, S.L., et al. 2005. Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood. 105:145-152.
46. Yarovoi, H., Nurden, A.T., Montgomery, R.R., Nurden, P., and Poncz, M. 2005. Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII. Blood. 105:4674-4676.
47. Wendell, C.M., Bellazzini, M.A., and Howes, D.S. 2004. Acquired factor VIII inhibitor presenting as a tongue hematoma. J. Emerg. Med. 26:411-414.
48. Moraca, R.J., and Ragni, M.V. 2002. Acquired anti-FVIII inhibitors in children. Haemophilia. 8:28-32.
49. Nathwani, A.C., Davidoff, A.M., and Linch, D.C. 2005. A review of gene therapy for haematological disorders. Br. J. Haematol. 128:3-17.
50. Pittman, D.D., Marquette, K.A., and Kaufman, R.J. 1994. Role of the B domain for factor VIII and factor V expression and function. Blood. 84:4214-4225.
51. Bi, L., et al. 1995. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat. Genet. 10:119-121.
52. Berryman, M.A., and Rodewald, R.D. 1990. An enhanced method for post-embedding immunocytochemical staining which preserves cell membranes. J. Histochem. Cytochem. 38:159-170.
53. Burleigh, B.A., Wells, C.W., Clarke, M.W., and Gardiner, P.R. 1993. An integral membrane glycoprotein associated with an endocytic compartment of Trypanosoma vivax: identification and partial characterization. J. Cell Biol. 120:339-352.
54. Connelly, S., et al. 1998. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 91:3273-3281.
55. Fakharzadeh, S.S., Zhang, Y., Sarkar, R., and Kazazian, H.H., Jr. 2000. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood. 95:2799-2805.
56. Parker, E.T., and Lollar, P. 2003. A quantitative measure of the efficacy of factor VIII in hemophilia A mice. Thromb. Haemost. 89:480-485.